Floatz logo

177lu-dota-sna040

Advanced Solid Tumors (Such as Cholangiocarcinoma)

SmartNuclide BiopharmaradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Advanced Solid Tumors (Such as Cholangiocarcinoma) cohort.

Asset / SponsorPhaseRating
Capecitabine
University of Washington
Phase 1CC
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 1CC
Elimusertib
National Cancer Institute (NCI)
Phase 1CC
Ropidoxuridine
National Cancer Institute (NCI)
Phase 1CC
cgx1321
Curegenix Inc.
Phase 1CC

View all 16 →

Same molecule, other indications

177lu-dota-sna040 is also rated in:

gastric cancerDormant
C
Indicative ·
39 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →
pancreatic neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →